Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CART-EGFR-IL13Ra2 cells |
Synonyms | |
Therapy Description |
CART-EGFR-IL13Ra2 are autologous T-lymphocytes engineered to express both EGFR epitope 806 and IL13Ra2, which potentially induce toxicity in tumor cells expressing EGFRvIII and IL13Ra2 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CART-EGFR-IL13Ra2 cells | CART-EGFR-IL13Ra2 cells are autologous T-lymphocytes engineered to express chimeric antigen receptors (CARs) that target EGFR epitope 806 and IL13Ra2, which potentially induce toxicity in tumor cells expressing EGFR vIII or IL13Ra2 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05168423 | Phase I | CART-EGFR-IL13Ra2 cells | CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM | Recruiting | USA | 0 |